FDA's Anti-Infective Drugs Advisory Committee
Executive Summary
Will meet Nov. 28-29 to discuss the use of fluorophotometry as an endpoint for ocular inflammation, and blepharitis as an indication for ocular quinolones. Discussion on the second day will focus on use of trimethoprim/sulfamethoxazole in treating traveler's diarrhea. Two NDAs will be considered in closed session. Meeting will be held in Parklawn Building, Conference Room D, beginning at 8 a.m. both days. . . .